FTO SUMOylation regulates the differentiation of bone marrow mesenchymal stromal cells in Inflammatory Bowel Disease-Induced Bone Loss

Gut-bone axis is critical for body homeostasis, but bone loss often complicates inflammatory bowel disease (IBD) with unclear mechanisms. Here, we found that IBD mice showed reduced bone formation, with bone marrow mesenchymal stromal cells (BMSCs) favoring adipogenesis over osteogenesis. Altered m6A modifications of BMSCs were confirmed in IBD mice, and further investigation revealed that the SUMOylation of FTO was involved. Nude mice with FTO-K216/357/365R mutation exhibited increased bone sizes and volumes versus control mice. Tocilizumab, an IL-6R monoclonal antibody, combined with AAV-FTO-3KR, mitigated bone loss and enhanced bone formation in IBD mice. Our findings reveal that SUMOylation of FTO is involved in the differentiation of BMSCs in mice with IBDs. The outcome could be blocked by redirecting differentiation toward osteoblasts treatment with AAV-FTO-3KR and the clinical-stage inhibitor, tocilizumab. Overall design: m6A transcriptomics assay was performed for investigating the downstream signaling pathways of BMSCs treated with AAV-FTO-WT or AAV-FTO-3KR.